TECX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

TECX ▲ 0.00% at T+20d

NEUTRAL call ✗ call lost 0.00% · α vs SPY -0.02% · entry $29.00 → $29.00

Next anchor: T+60d in 8w

Currently $28.56 · -1.52% from $29.00 entry

Entry anchored
May 7, 03:59 PM ET
via Databento tick

T+1d

-5.10%

call -5.10% · α -5.34%

$27.52

settled 5w ago

T+5d

+2.76%

call +2.76% · α +1.29%

$29.80

settled 27d ago

T+20d

0.00%

call 0.00% · α -0.02%

$29.00

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by increased R&D spend on TX45 and TX2100 trials. Cash burn was $16.9M in the quarter, leaving $236.9M in cash (runway into Q4 2028). The stock will move on pipeline milestones, not the financials — TX45 APEX Phase 2 topline in late Q4 2026/early Q1 2027 and TX2100 Phase 1a results in Q3 2026 are the key catalysts.

Actionable Insight

No near-term binary catalyst — the next major event is TX2100 Phase 1a data in Q3 2026, followed by TX45 APEX topline in late Q4 2026/early Q1 2027. Monitor cash burn trajectory and any early efficacy signals from the ongoing Phase 2 trials. The $236.9M cash position provides a long runway, reducing near-term dilution risk.

Key Facts

Q1 2026 net loss of $25.2M ($1.34/share) vs $15.9M ($0.93/share) in Q1 2025
Cash and equivalents $236.9M as of March 31, 2026, down from $253.8M at Dec 31, 2025
R&D expense $20.9M, up 60% YoY from $13.0M, driven by TX45 Phase 2 and TX2100 Phase 1a costs
TX45 APEX Phase 2 enrollment nearing completion; topline results expected late Q4 2026 or early Q1 2027
TX2100 Phase 1a in HHT dosed 4 cohorts; topline results expected by end of Q3 2026
TX45 ALPINE Phase 2 in PH-ILD initiated with first site activated in February 2026
Cash runway projected into Q4 2028, covering both Phase 2 readouts and TX2100 advancement

Financial Impact

Net loss widened $9.3M YoY to $25.2M; cash burn $16.9M in Q1 2026

net losscash positionR&D expense

Risk Factors

Phase 2 failure for TX45 in PH-HFpEF or PH-ILD would significantly impair pipeline value
TX2100 Phase 1a safety/tolerability miss could derail the HHT program
Cash burn rate is accelerating (R&D up 60% YoY); any trial delays could pressure runway assumptions

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

94% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3290500

6 reports for TECX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for TECX — sortable, filterable
	Type				Now
May 7, 2026 4w ago	8-K BEARISH ★ 5/10	$29.00 $29.00	· 0.00%	▲ +0.02%	$28.56 (+1.52%)
May 7, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$29.00 $29.00	· 0.00%	▼ −0.02%	$28.56 (−1.52%)
Apr 24, 2026 6w ago	DEFA14A NEUTRAL ★ 3/10	$28.75 $29.99	▲ +4.31%	▼ −0.64%	$28.56 (−0.66%)
Apr 3, 2026 9w ago	3 NEUTRAL ★ 2/10	$29.98 $29.65	▼ −1.10%	▼ −10.08%	$28.56 (−4.74%)
Mar 6, 2026 13w ago	Insider Cluster NEUTRAL ★ 4/10	$35.87 $29.98	▼ −16.42%	▼ −14.38%	$28.56 (−20.38%)
Feb 24, 2026 15w ago	8-K NEUTRAL ★ 3/10	$23.11 $31.06	▲ +34.40%	▲ +39.64%	$28.56 (+23.58%)

US Market Status

Market Closed — Opens Thu (10h 31m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access